Diffuse intrinsic pontine glioma

Posted 1 year ago by Wales Gene Park

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication(Biomede) Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

 Diffuse intrinsic pontine glioma /  London

Posted 1 year ago by Wales Gene Park

Some gliomas have a change (mutation ) in the BRAF gene called BRAF V600. The BRAF gene makes a protein that affects how cancers grow and divide. Dabrafenib and trametinib are targeted drugs. They work by blocking the action of the BRAF protein so possibly stopping the cancer growing or spreading. We know that the combination of dabrafenib and trametinib works for other cancers that have the BRAF V600 change. Researchers think it could help children and young people whose glioma has the BRAF V600 change. In this trial everyone who has a fast growing glioma will have dabrafenib and trametinib. Everyone who has a slow growing glioma will have either: dabrafenib and trametinib or carboplatin and vincristine (standard treatment ) The aims of this trial are to find: how well dabrafenib and trametinib works for children and young people with a glioma how dabrafenib and trametinib works in the...

 Diffuse intrinsic pontine glioma /  London

Posted 1 year ago by Wales Gene Park

A trial of targeted cancer therapies for children and young people with a brain tumour (BIOMEDE) Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

 Diffuse intrinsic pontine glioma /  London

Posted 1 year ago by Wales Gene Park

To assess brain tumours doctors can use scans such as an MRI scan. The MRI scan is good at showing where the tumour is and how big it is. But it can’t show other features of the tumour such as how fast it is growing. The researchers want to combine the MRI scan with another scan called a PET scan. They think that this combination might be better at showing these other features of the brain tumour. This information would be helpful when planning further tests or treatments. The main aim of this study is to see if the combination of an MRI scan and PET scan is better at giving more detailed information about a brain tumour than an MRI scan only.

 Diffuse intrinsic pontine glioma /  Cambridge


No post found